Skye Bioscience, Inc. (SKYE)
1.81
+0.03
(+1.69%)
USD |
NASDAQ |
Sep 04, 11:10
Skye Bioscience Free Cash Flow : -38.81M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.81M |
| March 31, 2026 | -42.44M |
| December 31, 2025 | -43.07M |
| September 30, 2025 | -41.53M |
| June 30, 2025 | -34.94M |
| March 31, 2025 | -31.32M |
| December 31, 2024 | -26.84M |
| September 30, 2024 | -22.47M |
| June 30, 2024 | -19.75M |
| March 31, 2024 | -14.61M |
| December 31, 2023 | -13.96M |
| September 30, 2023 | -14.56M |
| June 30, 2023 | -12.92M |
| March 31, 2023 | -13.92M |
| December 31, 2022 | -12.77M |
| September 30, 2022 | -10.35M |
| June 30, 2022 | -9.438M |
| March 31, 2022 | -8.124M |
| December 31, 2021 | -6.566M |
| September 30, 2021 | -6.336M |
| June 30, 2021 | -6.797M |
| March 31, 2021 | -6.154M |
| December 31, 2020 | -6.061M |
| September 30, 2020 | -5.771M |
| June 30, 2020 | -5.286M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.863M |
| December 31, 2019 | -6.028M |
| September 30, 2019 | -5.539M |
| June 30, 2019 | -4.867M |
| March 31, 2019 | -4.324M |
| December 31, 2018 | -3.947M |
| September 30, 2018 | -5.096M |
| June 30, 2018 | -4.38M |
| March 31, 2018 | -3.589M |
| December 31, 2017 | -3.351M |
| September 30, 2017 | -1.850M |
| June 30, 2017 | -2.262M |
| March 31, 2017 | -3.221M |
| December 31, 2016 | -3.564M |
| September 30, 2016 | -3.977M |
| June 30, 2016 | -4.763M |
| March 31, 2016 | -4.100M |
| December 31, 2015 | -3.692M |
| September 30, 2015 | -3.430M |
| June 30, 2015 | -3.097M |
| March 31, 2015 | -2.526M |
| December 31, 2014 | -1.778M |
| September 30, 2014 | -0.9479M |
| April 30, 2014 | 0.0236M |
| January 31, 2014 | -0.0075M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Regeneron Pharmaceuticals, Inc. | 3.575B |
| Viking Therapeutics, Inc. | -418.44M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -7.122M |
| Cash from Investing (Quarterly) | 7.142M |
| Cash from Financing (Quarterly) | -0.101M |
| Free Cash Flow Per Share (Quarterly) | -1.435 |
| Free Cash Flow to Equity (Quarterly) | -6.989M |
| Free Cash Flow to Firm (Quarterly) | -7.118M |
| Free Cash Flow Yield | -432.3% |